A Review of the Epidemiology of Lassa Fever in Nigeria
- PMID: 40572307
- PMCID: PMC12196193
- DOI: 10.3390/microorganisms13061419
A Review of the Epidemiology of Lassa Fever in Nigeria
Abstract
Lassa fever, a viral hemorrhagic illness that first came into the limelight as a clinical entity in 1969 when it was discovered in Northern Nigeria, is now found in other West African countries such as Sierra Leone, Liberia, Guinea, Togo, and the Benin Republic. Over the years, the disease, which is primarily transmitted from contact with infected mastomys rodents to humans, has the capability of secondary human-to-human transmission with significant morbidity and mortality, especially in healthcare settings. The disease is typically characterized by seasonal outbreaks, which peak during the dry season months of December to March. Lassa fever significantly impacts public health and the socioeconomic life of people in affected communities. In Nigeria, the Integrated Disease Surveillance and Response Strategy (IDSR), along with other medical countermeasures, have been employed to curtail the impact of the disease in endemic regions of Nigeria and other West Africa countries. The one-health approach to combat the disease is a promising strategy. This, along with the hope of a safe and effective vaccine, is a ray of hope on the horizon for public health authorities in Nigeria and other West African countries that the battle against Lassa fever might indeed end sooner than later.
Keywords: Lassa fever virus; epidemiology; outbreaks; response; surveillance.
Conflict of interest statement
The authors declares no conflict of interest.
Figures





Similar articles
-
The resurgence of Lassa fever in Nigeria: economic impact, challenges, and strategic public health interventions.Front Public Health. 2025 Jul 16;13:1574459. doi: 10.3389/fpubh.2025.1574459. eCollection 2025. Front Public Health. 2025. PMID: 40740381 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Drivers of Lassa fever in an endemic area of southwestern Nigeria (2017-2021): An epidemiological study.PLoS One. 2025 Jun 25;20(6):e0327143. doi: 10.1371/journal.pone.0327143. eCollection 2025. PLoS One. 2025. PMID: 40561161 Free PMC article.
-
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079. Health Technol Assess. 2024. PMID: 39046101 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
The resurgence of Lassa fever in Nigeria: economic impact, challenges, and strategic public health interventions.Front Public Health. 2025 Jul 16;13:1574459. doi: 10.3389/fpubh.2025.1574459. eCollection 2025. Front Public Health. 2025. PMID: 40740381 Free PMC article.
References
-
- Klitting R., Mehta S.B., Oguzie J.U., Oluniyi P.E., Pauthner M.G., Siddle K.J., Andersen K.G., Happi C.T., Sabeti P.C. Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics. Springer; Cham, Switzerland: 2020. Lassa virus genetics; pp. 23–65. Current Topics in Microbiology and Immunology. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources